Tuesday, June 20th at 7:00 PM ET
Presenters: Val R. Adams, PharmD, FCCP, BCOP
and Matt Farber, MA
This webcast will provide live credit (L) for those states requiring it.
Immunotherapy has revolutionized treatment and survival outcomes for patients with cancer. Due to their unique mechanisms of action (MOAs), response patterns, and safety profiles, these therapies differ greatly from cytotoxic agents and targeted therapies. Furthermore, the survival benefits of new and emerging immunotherapies are accompanied by high drug costs, making formulary decisions complex. As drug therapy and medical experts, specialty pharmacists play an integral role in cancer therapy and promoting cost-effective therapy utilization, and must be continually updated on these highly unique therapies. Through interactive case-based presentations and expert discussion, these live webcasts will present the most up-to-date information on the use of immunotherapies in oncology, their unique MOAs, response patterns, and AE management strategies. This activity will also address issues and challenges in incorporating these therapies into clinical practice to positively impact patient outcomes.
The goal of this activity is to enhance managed care and specialty pharmacists’ understanding of the evolving science, response assessment, adverse event management, and pharmacoeconomics regarding immunotherapies in oncology.
This educational initiative is intended for managed care and specialty pharmacists, as well as other pharmacists who are interested in immunotherapies in onoclogy. No prerequisites required.
- Activity Overview and Goals
- Introduction
- Role of the Immune System and Immunotherapy in Cancer
- Approved and Investigational Immune Checkpoint Inhibitors
- Immune-Related Response Criteria and Adverse Events
- Pharmacist Role
- Conclusions & Question & Answer Session
The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity. Upon the conclusion of this activity, the participant should be able to:
- DIFFERENTIATE the mechanism of action of immunotherapies from targeted therapies and chemotherapy.
- IDENTIFY currently approved and investigational immune checkpoint inhibitors and their clinical indications.
- RECOGNIZE unique disease response patterns and adverse events associated with immunotherapy treatment.
- DEVELOP strategies to educate patients and other HCPs on the efficacious and safe use of immunotherapy.
Val R. Adams, PharmD, FCCP, BCOP
Associate Professor
Pharmacy Practice and Science Department
College of Pharmacy
University of Kentucky
Lexington, Kentucky
Matt Farber, MA
Senior Director
Oncology Disease State
Walgreens Specialty Pharmacy
Deerfield, Illinois
 The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this application-based activity will provide a statement for 1.5 live contact hours of credit (0.15 CEUs). Successfully completing the activity and receiving credit includes: 1) attending the session; 2) watching, listening to, and participating in the activity; 3) completing the self-assessment instrument with a score of at least 70%. A statement of CE credit will available for download following successful completion of the educational activity. UAN: 0064-0000-17-207-L01-P. CE credit will be submitted to the NABP CPE Monitor within 30 days. It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted..
NABP e-PROFILE ID NUMBER: Pharmacists or pharmacy technicians with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: https://nabp.pharmacy/cpe-monitor-service/cpe-monitor-faqs/.
To receive credit for your participation in this activity, all pharmacists must include their NABP e-Profile ID number, along with their month and date of birth. If incorrect information is provided, this will result in "rejected" status from the CPE Monitor. It is the responsibility of the participant to notify The University of Tennessee (within the 60 day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.
Please allow up to 30 days for your credit to appear on CPE-Monitor.
It is the policy of The University of Tennessee College of Pharmacy that the faculty and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during the presentation(s). Detailed disclosures will be made in the presentations.
A participant, provider, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity provided or coprovided by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing at
gfarr@utasip.com. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.
There is no fee for this educational activity.
|